Use of ctDNA in identifying an actionable BRAF mutation in stage 4 metastatic melanoma

被引:0
|
作者
Bennett, Charlotte [1 ]
Morgan, Sian [2 ]
Aboud, Karam [1 ]
Frazer, Ricky Dylan [1 ]
机构
[1] Velindre Univ NHS Trust, Oncol, Cardiff, Wales
[2] All Wales Med Genet Serv, Oncol, Cardiff, Wales
关键词
Skin cancer; Oncology; Malignant disease and immunosuppression; Cancer intervention;
D O I
10.1136/bcr-2022-254268
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The identification of genetic variants in melanoma has enabled the development of targeted therapies. Under the National Institute for Health and Care Excellence (NICE) guidance, patients with BRAF V600E variant are eligible for BRAF and MEK inhibitor therapy. For those with advanced or highly symptomatic disease, a rapid response to treatment is often seen. Current practice relies on tissue biopsy to perform immunohistochemistry (IHC) or next generation sequencing (NGS) to identify these variants; however, this can take up to 2 weeks. In patients with widespread disease, rapid initiation of treatment can be lifesaving.We describe a case in which hotspot circulating tumour DNA (ctDNA) analysis confirmed BRAF variant 6 days prior to biopsy results. This was utilised to expedite treatment initiation and symptomatically, the patient had initial improvement within a few days.This article demonstrates the potential value of ctDNA analysis and the need for further research into this as an alternative to NGS for patients with rapidly progressive disease.
引用
收藏
页数:3
相关论文
共 50 条
  • [31] BRAF V600 Mutation Profile of Metastatic Melanoma in the Thrace Region of Turkey
    Can, Nuray
    Tastekin, Ebru
    Deniz Yalta, Tulin
    Sut, Necdet
    Korkmaz, Selma
    Usta, Ufuk
    Oz Puyan, Fulya
    Genc, Ezgi
    Cezik, Mert
    Binboga Tutug, Busem
    Kostek, Osman
    Tozkir, Hilmi
    TURKISH JOURNAL OF PATHOLOGY, 2018, 34 (02) : 134 - 142
  • [32] Radiotherapy utilization in BRAF mutation-tested metastatic melanoma in the targeted therapy era
    Gorayski, Peter
    Dzienis, Marcin
    Foote, Matthew
    Atkinson, Victoria
    Burmeister, Elizabeth
    Burmeister, Bryan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (02) : E117 - E123
  • [33] Detection of BRAF Mutation in Metastatic Melanoma Utilizing Cell-Transferred Cytological Smears
    Chen, Shaoxiong
    Randolph, Melissa
    Cramer, Harvey M.
    Watkins, Tracy
    McCullough, Holly
    Post, Kristin M.
    Sen, Joyashree D.
    Cheng, Liang
    Wu, Howard H.
    ACTA CYTOLOGICA, 2014, 58 (05) : 478 - 482
  • [34] Treatment pattern of systemic therapies in patients with metastatic melanoma and BRAF mutation test.
    Fu, Alex Z.
    Li, Zhiyi
    Tang, Jackson
    Grzegorzewski, Kris
    Mahmood, Syed
    Whisman, Tyler
    Quadri, Syed
    Qiu, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] A promising targeted therapy for metastatic melanoma with BRAF-V600E mutation
    Darbon, J. -M.
    BULLETIN DU CANCER, 2010, 97 (12) : 1413 - 1414
  • [36] The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma
    Letizia Porcelli
    Gabriella Guida
    Tiziana Cocco
    Anna E. Quatrale
    Rosa M Iacobazzi
    Diana A Stolfa
    Imma Maida
    Anna Ferretta
    Claudia Grieco
    Stefania Guida
    Sabino Strippoli
    Stefania Tommasi
    Michele Guida
    Amalia Azzariti
    Journal of Translational Medicine, 13 (Suppl 1)
  • [37] Treatment response under BRAF/MEK inhibition in metastatic malignant melanoma with BRAF L597R mutation
    Moufarrej, A.
    Lindhof, H. H.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 88 - 88
  • [38] The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma
    Poizeau, Florence
    Balusson, Frederic
    Lemaitre, Florian
    Tron, Camille
    Pracht, Marc
    Russo, David
    Dinulescu, Monica
    Lesimple, Thierry
    Oger, Emmanuel
    Dupuy, Alain
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (04) : 482 - 490
  • [39] Alternative use of BRAF inhibitors in patients with metastatic melanoma unable to swallow pills
    Fleury, M. Darrigade
    Regnault, Marie Masson
    Cales, S.
    Frouin, E.
    Wierbiecka-Hainaut, Ewa
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (04) : 996 - 999
  • [40] BRAF Mutation Status in Primary, Recurrent, and Metastatic Malignant Melanoma and Its Relation to Histopathological Parameters
    Spathis, Aris
    Katoulis, Alexander C.
    Damaskou, Vasileia
    Liakou, Aikaterini, I
    Kottaridi, Christine
    Leventakou, Danai
    Sgouros, Dimitrios
    Mamantopoulos, Andreas
    Rigopoulos, Dimitrios
    Karakitsos, Petros
    Panayiotides, Ioannis G.
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2019, 9 (01): : 54 - 62